Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the results of a study comparing the efficacy and safety of pegfilgrastim versus filgrastim in patients with heavily pretreated multiple myeloma who have previously been treated with pomalidomide plus dexamethasone. The study found that pegfilgrastim seemed to reduce the incidence of severe neutropenia and infections, and was well tolerated. This interview took place during the 2021 European Myeloma Network (EMN) congress.